Aurobindo Pharma Ltd has introduced an innovative HIV triple combination tablet specially designed for children living with HIV in low- and middle-income countries. The company’s shares exhibited little change in response to the announcement, opening at Rs 872.65 around 9.31 am on August 17. The tablet aims to address the treatment needs of young patients and is set to offer improved medical support.
This significant development is a result of Aurobindo Pharma’s collaboration with ViiV Healthcare, which has granted the company a paediatric dolutegravir voluntary license. This arrangement allows Aurobindo Pharma to produce and distribute the tablet across 123 low and middle-income countries, including India.
The United States Food and Drug Administration (USFDA) has granted tentative approval for this pioneering tablet formulation, comprising Abacavir 60 mg, Lamivudine 30 mg, and Dolutegravir 5 mg (pALD). This combination therapy is targeted at treating children living with HIV.